EyePoint Pharmaceuticals Shares Slide 32% on Duravyu Trial Missing Primary Endpoint
By Denny Jacob
EyePoint Pharmaceuticals shares slide 32% after disclosing that topline results from a Phase 2 clinical trial evaluating Duravyu in non-proliferative diabetic retinopathy didn't meet the pre-specified primary endpoint.
Shares were trading around $13.46 after resuming trading at 7:30 a.m. ET following a halt at 6:55 a.m. ET. The stock is down 15% on the year so far.
Non-proliferative diabetic retinopathy is an early stage of diabetic retinopathy, a leading cause of blindness in working age adults, in which symptoms may be mild or nonexistent.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 06, 2024 08:05 ET (12:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy
-
Snowflake Earnings: Mixed News, But Signs of Stability
-
Nvidia Earnings: AI Demand Smashes Expectations Again
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending